In a tiered approach using in silico network pharmacology and molecular docking, targets of 22-(4′py)-JA against NSCLC were first identified, and it was validated that ERK1/2 and MEK1 played potential key roles in the pharmacological mechanism of anti-lung cancer activity. The gene discussed is MAPK3; the disease is lung cancer.